DN203316, a novel PPARδ agonist, suppresses ferroptotic signaling and fibrogenesis in metabolic dysfunction-associated steatohepatitis.
- DOI
- 10.1038/s12276-026-01740-0
- Published
- 2026 Jun
- Container
- Experimental & molecular medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s12276-026-01740-0,
title = {DN203316, a novel PPARδ agonist, suppresses ferroptotic signaling and fibrogenesis in metabolic dysfunction-associated steatohepatitis.},
author = {Kim YJ and Kim J and An DY and Park M and Jeong GH and Jin J and Kim MK and Chin J and Choi YK and Park KG},
year = {2026},
journal = {Experimental \& molecular medicine},
doi = {10.1038/s12276-026-01740-0},
url = {https://doi.org/10.1038/s12276-026-01740-0}
}RIS
TY - JOUR TI - DN203316, a novel PPARδ agonist, suppresses ferroptotic signaling and fibrogenesis in metabolic dysfunction-associated steatohepatitis. AU - Kim YJ AU - Kim J AU - An DY AU - Park M AU - Jeong GH AU - Jin J AU - Kim MK AU - Chin J AU - Choi YK AU - Park KG PY - 2026 JO - Experimental & molecular medicine DO - 10.1038/s12276-026-01740-0 UR - https://doi.org/10.1038/s12276-026-01740-0 ER -
APA
YJ, K., J, K., DY, A., M, P., GH, J., J, J., MK, K., J, C., YK, C., & KG, P. (2026). DN203316, a novel PPARδ agonist, suppresses ferroptotic signaling and fibrogenesis in metabolic dysfunction-associated steatohepatitis.. Experimental & molecular medicine. https://doi.org/10.1038/s12276-026-01740-0
Source records
- pubmed · retrieved 2026-09-26T16:27:46.988Z